470P Progression-free survival and response rate with EGFR tyrosine kinase inhibitor treatment according to EGFR mutation subtype in advanced lung adenocarcinoma

Annals of Oncology ◽

10.1093/annonc/mdw594.034 ◽

2016 ◽

Vol 27 (suppl_9) ◽

Author(s):

C.S. Chai ◽

C.K. Liam ◽

Y.K. Pang ◽

K.S. Kow ◽

C.K. Wong ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Egfr Mutation ◽

Response Rate ◽

Kinase Inhibitor ◽

Progression Free Survival ◽

Egfr Tyrosine Kinase Inhibitor ◽

Free Survival ◽

Inhibitor Treatment

Download Full-text

470P Progression-free survival and response rate with EGFR tyrosine kinase inhibitor treatment according to EGFR mutation subtype in advanced lung adenocarcinoma

Annals of Oncology ◽

10.1016/s0923-7534(21)00628-1 ◽

2016 ◽

Vol 27 ◽

pp. ix150-ix151

Author(s):

C.S. Chai ◽

C.K. Liam ◽

Y.K. Pang ◽

K.S. Kow ◽

C.K. Wong ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Egfr Mutation ◽

Response Rate ◽

Kinase Inhibitor ◽

Progression Free Survival ◽

Egfr Tyrosine Kinase Inhibitor ◽

Free Survival ◽

Inhibitor Treatment

Download Full-text

EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer

Medicine ◽

10.1097/md.0000000000006151 ◽

2017 ◽

Vol 96 (7) ◽

pp. e6151 ◽

Author(s):

Jin-Qiu Yuan ◽

Yue-Lun Zhang ◽

Hai-Tao Li ◽

Chen Mao

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Nonsmall Cell Lung Cancer ◽

Egfr Tyrosine Kinase Inhibitor ◽

Inhibitor Treatment ◽

Egfr Mutation Testing

Download Full-text

An analysis of serum heparan sulfate concentration and EGFR tyrosine kinase inhibitor treatment in patients with non-small cell lung adenocarcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.10601 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 10601-10601

Author(s):

M. Nishio ◽

T. Yamanaka ◽

K. Matsumoto ◽

H. Kimura ◽

K. Sakai ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Heparan Sulfate ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Sulfate Concentration ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Inhibitor Treatment

Download Full-text

Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor

PLoS ONE ◽

10.1371/journal.pone.0203625 ◽

2018 ◽

Vol 13 (9) ◽

pp. e0203625 ◽

Author(s):

Kousuke Watanabe ◽

Atsushi Yasumoto ◽

Yosuke Amano ◽

Hidenori Kage ◽

Yasushi Goto ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Mean Platelet Volume ◽

Kinase Inhibitor ◽

Progression Free Survival ◽

Platelet Volume ◽

Egfr Tyrosine Kinase Inhibitor ◽

Free Survival ◽

Lymphocyte To Monocyte Ratio ◽

Download Full-text

Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-013-1495-0 ◽

2013 ◽

Vol 139 (10) ◽

pp. 1691-1700 ◽

Author(s):

Tatsuya Yoshida ◽

Genichiro Ishii ◽

Koichi Goto ◽

Kiyotaka Yoh ◽

Seiji Niho ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Abstract 1756: Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma

10.1158/1538-7445.am2014-1756 ◽

2014 ◽

Author(s):

Hui-Yi Shiao ◽

Tsu-An Hsu ◽

Wen-Hsing Lin ◽

Tsong-Toh Yang ◽

Hui-Fang Hsieh ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma

10.1186/s12885-018-5116-9 ◽

2018 ◽

Vol 18 (1) ◽

Author(s):

Eun Young Kim ◽

Arum Kim ◽

Gaeun Lee ◽

Hangsuck Lee ◽

Yoon Soo Chang

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy

Lung Cancer ◽

10.1016/j.lungcan.2019.08.029 ◽

2019 ◽

Vol 137 ◽

pp. 76-84 ◽

Author(s):

Min-Shu Hsieh ◽

Mong-Wei Lin ◽

Yi-Hsuan Lee

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Inhibitor Treatment

Download Full-text

P38.12 Lung Adenocarcinoma with Sarcomatoid Transformation after Tyrosine Kinase Inhibitor Treatment and Chemotherapy

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.01.793 ◽

2021 ◽

Vol 16 (3) ◽

pp. S462-S463

Author(s):

M. Lin ◽

M. Hsieh ◽

Y. Lee

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Inhibitor Treatment

Download Full-text

PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor–Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-15-2724 ◽

2016 ◽

Vol 22 (21) ◽

pp. 5370-5382 ◽

Author(s):

De-Wei Wu ◽

Tzu-Chin Wu ◽

Chih-Yi Chen ◽

Huei Lee

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Therapeutic Target ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Akt Signaling ◽

Novel Therapeutic

Download Full-text